Tango Therapeutics Quarterly Income Statement
NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tango Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Tango Therapeutics generated $0 in revenue, down 100.0% from the same quarter a year earlier. Tango Therapeutics reported a net loss of $55.3 million, compared with a loss of $38.9 million a year earlier. Diluted earnings per share came in at -$0.37.
Summary generated from market data by MetaCap's automated system. Methodology
Tango Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 53.81M | 3.18M | 5.39M | 4.12M | 11.61M | 19.88M | 6.47M | 5.43M | 10.73M |
| Revenue growth (YoY) | -100.00% | -100.00% | -100.00% | +363.61% | -83.99% | -16.67% | -24.19% | +8.15% | +36.15% | +12.23% | -15.29% | +55.09% |
| Operating Expenses | 59.78M | 48.77M | 41.86M | 39.74M | 44.15M | 47.92M | 45.03M | 44.48M | 49.43M | 48.73M | 40.44M | 36.36M |
| Research & Development | 37.20M | 33.53M | 32.10M | 30.82M | 32.81M | 36.44M | 33.94M | 33.26M | 38.65M | 38.06M | 31.34M | 27.15M |
| Operating Income | -59.78M | -48.77M | -41.86M | 14.07M | -40.97M | -42.53M | -40.91M | -32.88M | -29.55M | -42.26M | -35.01M | -25.63M |
| Other Income (Expense) | 4.45M | 3.26M | 3.06M | 1.80M | 2.15M | 2.69M | 3.29M | 3.77M | 4.07M | 4.38M | 4.30M | 3.39M |
| Pretax Income | -55.34M | -45.51M | -38.80M | 15.87M | -38.82M | -39.84M | -37.62M | -29.11M | -25.49M | -37.87M | -30.72M | -22.24M |
| Income Tax | 1.00K | 1.00K | -55.00K | -10.00K | 35.00K | 34.00K | 49.00K | 54.00K | 65.00K | 40.00K | 47.00K | 23.00K |
| Net Income | -55.34M | -45.51M | -38.75M | 15.88M | -38.85M | -39.88M | -37.67M | -29.17M | -25.55M | -37.91M | -30.76M | -22.26M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.37 | -0.32 | -0.30 | 0.14 | -0.35 | -0.36 | -0.33 | -0.27 | -0.24 | -0.35 | -0.30 | -0.23 |
| EPS (Diluted) | -0.37 | -0.32 | -0.29 | 0.13 | -0.35 | -0.36 | -0.33 | -0.27 | -0.24 | -0.35 | -0.30 | -0.23 |
| Shares Outstanding (Basic) | 149.88M | 143.58M | — | 110.97M | 110.54M | 110.30M | — | 108.51M | 108.31M | 108.17M | — | 97.03M |
| Shares Outstanding (Diluted) | 149.88M | 143.58M | — | 117.78M | 110.54M | 110.30M | — | 108.51M | 108.31M | 108.17M | — | 97.03M |
| EBITDA | -59.36M | -48.31M | -41.38M | 14.63M | -40.34M | -41.91M | -40.29M | -32.26M | -28.92M | -41.63M | -34.40M | -25.01M |
| Operating Margin | — | — | — | 26.15% | -1287.87% | -788.76% | -993.68% | -283.26% | -148.69% | -652.99% | -644.69% | -238.78% |
| Net Margin | — | — | — | 29.52% | -1221.41% | -739.54% | -914.99% | -251.29% | -128.56% | -585.91% | -566.43% | -207.45% |
This table shows 12 quarterly periods of Tango Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow TNGX's reporting calendar. What is a income statement?